Glucagon-Like Peptide 1 Market Trends: Brand Comparison, Technology, and Industry Data Analysis
Abstract: Glucagon-like peptide-1 (GLP-1) market analysis reveals a surge driven by obesity and diabetes therapeutics. Brand comparison (e.g., Novo Nordisk’s Ozempic vs. Eli Lilly’s Mounjaro) highlights efficacy and delivery technology differences. Industry data shows a CAGR exceeding 15%, with peptide synthesis advancements improving stability. Key trends include oral formulations and biosimilar entry. Product parameters (purity >98%, half-life variations) and logistics (cold-chain compliance) are critical. Factory GMP certifications and FDA/EMA approvals dominate quality benchmarks. Selection criteria prioritize bioavailability, side-effect profiles, and patent status. The sector’s future hinges on expanded indications and scalable manufacturing.